The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
04
07
2019
pubmed:
15
4
2020
medline:
3
2
2021
entrez:
15
4
2020
Statut:
ppublish
Résumé
The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of ovarian neoplasms specifically related to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, gynecologic oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
Identifiants
pubmed: 32285271
doi: 10.1245/s10434-020-08322-y
pii: 10.1245/s10434-020-08322-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1780-1787Investigateurs
Claire Hoppenot
(C)
Darryl Schuitevoerder
(D)
Francisco J Izquierdo
(FJ)
Alejandro Plana
(A)
Bhavana Pothuri
(B)
S Diane Yamada
(SD)
Josephine Kim
(J)
Nita Karnik Lee
(NK)
Daniel E Abbott
(DE)
Sherif Abdel-Misih
(S)
Steven A Ahrendt
(SA)
Mazin Al-Kasspooles
(M)
Farin Amersi
(F)
Amanda K Arrington
(AK)
Brian Badgwell
(B)
Robert M Barone
(RM)
Joel M Baumgartner
(JM)
Richard N Berri
(RN)
Lana Bijelic
(L)
Dan G Blazer
(DG)
Wilbur B Bowne
(WB)
Charles Komen Brown
(CK)
Daniel V Catenacci
(DV)
Carlos H F Chan
(CHF)
David B Chapel
(DB)
Clifford S Cho
(CS)
M Haroon A Choudry
(MHA)
Callisia N Clarke
(CN)
James C Cusack
(JC)
Abraham H Dachman
(AH)
Jeremiah L Deneve
(JL)
Sean P Dineen
(SP)
Oliver S Eng
(OS)
Leopoldo J Fernandez
(LJ)
James Fleshman
(J)
T Clark Gamblin
(TC)
Alexandra Gangi
(A)
Georgios V Georgakis
(GV)
Erin W Gilbert
(EW)
Martin D Goodman
(MD)
Travis E Grotz
(TE)
Vadim Gushchin
(V)
Nader Hanna
(N)
Carla Harmath
(C)
Andrea Hayes-Jordan
(A)
Aliya N Husain
(AN)
Kamran Idrees
(K)
Chukwuemeka Ihemelandu
(C)
Fabian M Johnston
(FM)
David Jiang
(D)
John M Kane
(JM)
Giorgos Karakousis
(G)
Kaitlyn J Kelly
(KJ)
Timothy J Kennedy
(TJ)
Xavier M Keutgen
(XM)
Hedy Lee Kindler
(HL)
Michael D Kluger
(MD)
Ricardo R Lastra
(RR)
Byrne Lee
(B)
Lloyd A Mack
(LA)
Ugwuji N Maduekwe
(UN)
Grace Z Mak
(GZ)
Joshua M V Mammen
(JMV)
Melvy Sarah Mathew
(MS)
Marcovalerio Melis
(M)
Nelya Melnitchouk
(N)
Ryan P Merkow
(RP)
Harveshp Mogal
(H)
Mecker G Möller
(MG)
John Moroney
(J)
Aytekin Oto
(A)
Colette R Pameijer
(CR)
Sam G Pappas
(SG)
Patricio M Polanco
(PM)
Blase N Polite
(BN)
Sanjay S Reddy
(SS)
Richard Royal
(R)
George Salti
(G)
Armando Sardi
(A)
Maheswari Senthil
(M)
Namrata Setia
(N)
Scott K Sherman
(SK)
Lucas Sideris
(L)
Joseph Skitzki
(J)
Sandy Tun
(S)
Jula Veerapong
(J)
Konstantinos I Votanopoulos
(KI)
Michael G White
(MG)
Joshua H Winer
(JH)
Shu-Yuan Xiao
(SY)
Rhonda K Yantiss
(RK)
Nita Ahuja
(N)
Andrew M Lowy
(AM)
H Richard Alexander
(HR)
Jesus Esquivel
(J)
Jason M Foster
(JM)
Daniel M Labow
(DM)
Laura A Lambert
(LA)
Edward A Levine
(EA)
Charles Staley
(C)
Paul H Sugarbaker
(PH)
David L Bartlett
(DL)
Kiran Turaga
(K)
Références
Chicago Consensus Working Group. The Chicago Consensus Guidelines for Peritoneal Surface Malignancies: Introduction. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08318-8 .
doi: 10.1245/s10434-020-08318-8
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Methodology. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08317-9 .
doi: 10.1245/s10434-020-08317-9
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Standards. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08325-9 .
doi: 10.1245/s10434-020-08325-9
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08316-w .
doi: 10.1245/s10434-020-08316-w
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08315-x .
doi: 10.1245/s10434-020-08315-x
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08320-0 .
doi: 10.1245/s10434-020-08320-0
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08324-w .
doi: 10.1245/s10434-020-08324-w
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08321-z .
doi: 10.1245/s10434-020-08321-z
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumor. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08319-7 .
doi: 10.1245/s10434-020-08319-7
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08323-x .
doi: 10.1245/s10434-020-08323-x
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–1388.
pubmed: 24767708
Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(24):3621–3627.
pubmed: 17704411
Asher V, Lee J, Bali A. Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Med Oncol. 2012;29(3):2005–2009.
pubmed: 21735143
Huang H, Li YJ, Lan CY, et al. Clinical significance of ascites in epithelial ovarian cancer. Neoplasma. 2013;60(5):546–552.
pubmed: 23790174
Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382–390.
pubmed: 22274685
pmcid: 3727895
Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2(4):482–490.
pubmed: 26720728
pmcid: 4845939
Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108(44):18032–18037.
pubmed: 22006311
pmcid: 3207658
Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284.
pubmed: 28754483
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505.
pubmed: 30345884
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234–1244.
pubmed: 19189349
Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680–1687.
pubmed: 30413383
Axtell AE, Lee MH, Bristow RE, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007;25(4):384–389.
pubmed: 17264334
Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13(8):1156–1161.
pubmed: 16791447
Hansen JM, Sood AK, Coleman RL, et al. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018;151(3):428–432.
pubmed: 30366647
pmcid: 6281799
El-Agwany AS. Laparoscopy and computed tomography imaging in advanced ovarian tumors: a roadmap for prediction of optimal cytoreductive surgery. Gynecol Minim Invasive Ther. 2018;7(2):66–69.
pubmed: 30254940
pmcid: 6113992
Coleman RL, Enserro D, Spirtos N, et al. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2018;36(15_suppl):5501–5501.
Du Bois A, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clinical Oncol. 2017;35(15_suppl):5501–5501.
Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106(9):1933–1939.
pubmed: 16572412
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483.
pubmed: 22204724
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496.
pubmed: 22204725
Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020–1026.
pubmed: 23948349
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.
pubmed: 16394300
Walker JL. Intraperitoneal chemotherapy for ovarian cancer. Gynecol Oncol. 2016;142(1):1–2.
pubmed: 27328898
Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D; Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(4):437–443.
pubmed: 17264340
Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374(8):738–748.
pubmed: 26933849
pmcid: 5081077
Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15(4):396–405.
pubmed: 24582486
Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107(4):588–591.
pubmed: 22836511
pmcid: 3419956
Ledermann JA, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–1392.
pubmed: 22452356
Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936.
pubmed: 26115797
pmcid: 4648090
Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.
pubmed: 27908594
Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164.
pubmed: 27717299
Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.
pubmed: 22529265
pmcid: 3646321
Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961.
pubmed: 28916367
pmcid: 5901715
Buda A, Floriani I, Rossi R, et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer. 2004;90(11):2112–2117.
pubmed: 15150623
pmcid: 2409494
Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176–3182.
pubmed: 18591555
Lortholary A, Largillier R, Weber B, et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO). Ann Oncol. 2012;23(2):346–352.
pubmed: 21562072
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–1308.
pubmed: 24637997
Provencher DM, Gallagher CJ, Parulekar WR, et al. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann Oncol. 2018;29(2):431–438.
pubmed: 29186319
van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.
pubmed: 29342393
Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–1575.
pubmed: 25391263
Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578–1589.
pubmed: 26453145
Petrillo M, Anchora LP, Scambia G, Fagotti A. Cytoreductive surgery plus platinum-based hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: a promising integrated approach to improve locoregional control. Oncologist. 2016;21(5):532–534.
pubmed: 27009941
pmcid: 4861369
Ledermann JA, Luvero D, Shafer A, et al. Gynecologic Cancer Intergroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S14–19.
pubmed: 25341574
Delhorme JB, Severac F, Averous G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. Br J Surg. 2018;105(6):668–676.
pubmed: 29412465
Mercier F, Bakrin N, Bartlett DL, et al. Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol. 2018;25(6):1668–1675.
pubmed: 29637438